CA2645982A1 - Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique - Google Patents

Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique Download PDF

Info

Publication number
CA2645982A1
CA2645982A1 CA2645982A CA2645982A CA2645982A1 CA 2645982 A1 CA2645982 A1 CA 2645982A1 CA 2645982 A CA2645982 A CA 2645982A CA 2645982 A CA2645982 A CA 2645982A CA 2645982 A1 CA2645982 A1 CA 2645982A1
Authority
CA
Canada
Prior art keywords
ave5026
treatment
patients
incidence
bleedings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2645982A
Other languages
English (en)
Inventor
Dominique Destree
Paul Chew
Sophie Claudel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to CA2645982A priority Critical patent/CA2645982A1/fr
Publication of CA2645982A1 publication Critical patent/CA2645982A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2645982A 2008-12-05 2008-12-05 Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique Abandoned CA2645982A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2645982A CA2645982A1 (fr) 2008-12-05 2008-12-05 Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2645982A CA2645982A1 (fr) 2008-12-05 2008-12-05 Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Publications (1)

Publication Number Publication Date
CA2645982A1 true CA2645982A1 (fr) 2010-06-05

Family

ID=42229321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2645982A Abandoned CA2645982A1 (fr) 2008-12-05 2008-12-05 Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Country Status (1)

Country Link
CA (1) CA2645982A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446891A1 (fr) * 2010-10-28 2012-05-02 Aventis Pharma S.A. Semuloparin pour utilisation comme traitement antithrombotique en chirurgie abdominale majeure avec une sécurité améliorée en termes de saignements cliniquement pertinents et saignements majeurs
WO2012055843A1 (fr) * 2010-10-28 2012-05-03 Aventis Pharma S.A. Sémuloparine pour la prévention d'une trombo-embolie veineuse majeure chez un patient subissant une chirurgie abdominale majeure
US20130101524A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
US20130102566A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
US20130102565A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopedic surgery

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130101524A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
US20130102566A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
US20130102565A1 (en) * 2010-06-25 2013-04-25 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopedic surgery
EP2446891A1 (fr) * 2010-10-28 2012-05-02 Aventis Pharma S.A. Semuloparin pour utilisation comme traitement antithrombotique en chirurgie abdominale majeure avec une sécurité améliorée en termes de saignements cliniquement pertinents et saignements majeurs
WO2012055844A1 (fr) * 2010-10-28 2012-05-03 Aventis Pharma S.A. Sémluparine destinée à être utilisée en tant que traitement antithrombotique dans une chirurgie abdominale majeure ayant une sécurité améliorée en termes de saignements cliniquement pertinents et de saignements majeurs
WO2012055843A1 (fr) * 2010-10-28 2012-05-03 Aventis Pharma S.A. Sémuloparine pour la prévention d'une trombo-embolie veineuse majeure chez un patient subissant une chirurgie abdominale majeure

Similar Documents

Publication Publication Date Title
Eriksson et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
Fuji et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
Cosmi et al. Old and new heparins
CA2645982A1 (fr) Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique
Hoy et al. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis
AU2021248905A1 (en) Method for reducing the occurrence of thrombosis or thromboembolism
TWI516269B (zh) 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
Mousa The low molecular weight heparin, tinzaparin, in thrombosis and beyond
US6258798B1 (en) Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
AU2008255191A1 (en) Use of Ave5026 for minimizing the incidence of bleedings during an antithrombotic treatment
JPH10218902A (ja) 低分子化硫酸化多糖、その製造法及び医薬組成物
Turpie Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice
US20120070471A1 (en) Administration of enoxoparin sodium to patients 75 years and older with st-segment elevation myocardial infarction
Del Bono et al. Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
Kishimoto et al. M118–A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes
CA2458852A1 (fr) Compositions antithrombotiques comportant de l'heparine de faible poids molecule et du dermatane sulfate de poids moleculaire
JP2007523876A (ja) Ｈｉｔ患者をアルガトロバンを用いて治療する方法
BRPI0806039A2 (pt) uso de ave5026 para minimizar a incidência de sangramentos durante um tratamento antitrombótico
US20090149423A1 (en) Use for a very low molecular weight heparins
AU2001291549A1 (en) Antithrombotic compositions
Kalkana Conventional anticoagulant therapy
Jones et al. Is there a role for pentosan polysulfate in the prevention of calcium oxalate stones?
AU2012203519A1 (en) Treatment of cytokine mediated conditions
Bates et al. The new heparins

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20131205